News
NEWTOWN, PA — Traws Pharma, Inc. (NASDAQ: TRAW) announced encouraging topline results from preclinical studies evaluating tivoxavir marboxil (TXM) as a potential treatment for H5N1 bird flu.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback